189 related articles for article (PubMed ID: 22951888)
1. Genetic modulation of lipid profiles following lifestyle modification or metformin treatment: the Diabetes Prevention Program.
Pollin TI; Isakova T; Jablonski KA; de Bakker PI; Taylor A; McAteer J; Pan Q; Horton ES; Delahanty LM; Altshuler D; Shuldiner AR; Goldberg RB; Florez JC; Franks PW;
PLoS Genet; 2012; 8(8):e1002895. PubMed ID: 22951888
[TBL] [Abstract][Full Text] [Related]
2. Comprehensive Analysis of Established Dyslipidemia-Associated Loci in the Diabetes Prevention Program.
Varga TV; Winters AH; Jablonski KA; Horton ES; Khare-Ranade P; Knowler WC; Marcovina SM; Renström F; Watson KE; Goldberg R; Florez JC; Pollin TI; Franks PW
Circ Cardiovasc Genet; 2016 Dec; 9(6):495-503. PubMed ID: 27784733
[TBL] [Abstract][Full Text] [Related]
3. Change in adiponectin explains most of the change in HDL particles induced by lifestyle intervention but not metformin treatment in the Diabetes Prevention Program.
Goldberg RB; Temprosa M; Mele L; Orchard T; Mather K; Bray G; Horton E; Kitabchi A; Krakoff J; Marcovina S; Perreault L; White N;
Metabolism; 2016 May; 65(5):764-775. PubMed ID: 27085783
[TBL] [Abstract][Full Text] [Related]
4. Lifestyle and metformin treatment favorably influence lipoprotein subfraction distribution in the Diabetes Prevention Program.
Goldberg R; Temprosa M; Otvos J; Brunzell J; Marcovina S; Mather K; Arakaki R; Watson K; Horton E; Barrett-Connor E
J Clin Endocrinol Metab; 2013 Oct; 98(10):3989-98. PubMed ID: 23979954
[TBL] [Abstract][Full Text] [Related]
5. PIOfix-study: effects of pioglitazone/metformin fixed combination in comparison with a combination of metformin with glimepiride on diabetic dyslipidemia.
Pfützner A; Schöndorf T; Tschöpe D; Lobmann R; Merke J; Müller J; Lehmann U; Fuchs W; Forst T
Diabetes Technol Ther; 2011 Jun; 13(6):637-43. PubMed ID: 21457065
[TBL] [Abstract][Full Text] [Related]
6. Updated genetic score based on 34 confirmed type 2 diabetes Loci is associated with diabetes incidence and regression to normoglycemia in the diabetes prevention program.
Hivert MF; Jablonski KA; Perreault L; Saxena R; McAteer JB; Franks PW; Hamman RF; Kahn SE; Haffner S; ; Meigs JB; Altshuler D; Knowler WC; Florez JC;
Diabetes; 2011 Apr; 60(4):1340-8. PubMed ID: 21378175
[TBL] [Abstract][Full Text] [Related]
7. 'Fat mass and obesity associated' gene (FTO): no significant association of variant rs9939609 with weight loss in a lifestyle intervention and lipid metabolism markers in German obese children and adolescents.
Müller TD; Hinney A; Scherag A; Nguyen TT; Schreiner F; Schäfer H; Hebebrand J; Roth CL; Reinehr T
BMC Med Genet; 2008 Sep; 9():85. PubMed ID: 18799002
[TBL] [Abstract][Full Text] [Related]
8. Causal Effects of Intensive Lifestyle and Metformin Interventions on Cardiovascular Disease Risk Factors in Pre-Diabetic People: An Application of G-Estimation.
Salimi Y; Fotouhi A; Mohammad K; Mansournia N; Mansournia MA
Arch Iran Med; 2017 Jan; 20(1):55-59. PubMed ID: 28112533
[TBL] [Abstract][Full Text] [Related]
9. The Combined Effect of Common Genetic Risk Variants on Circulating Lipoproteins Is Evident in Childhood: A Longitudinal Analysis of the Cardiovascular Risk in Young Finns Study.
Buscot MJ; Magnussen CG; Juonala M; Pitkänen N; Lehtimäki T; Viikari JS; Kähönen M; Hutri-Kähönen N; Schork NJ; Raitakari OT; Thomson RJ
PLoS One; 2016; 11(1):e0146081. PubMed ID: 26731281
[TBL] [Abstract][Full Text] [Related]
10. Association of apolipoprotein E gene polymorphisms with blood lipids and their interaction with dietary factors.
Shatwan IM; Winther KH; Ellahi B; Elwood P; Ben-Shlomo Y; Givens I; Rayman MP; Lovegrove JA; Vimaleswaran KS
Lipids Health Dis; 2018 Apr; 17(1):98. PubMed ID: 29712557
[TBL] [Abstract][Full Text] [Related]
11. Effects of genetic variants previously associated with fasting glucose and insulin in the Diabetes Prevention Program.
Florez JC; Jablonski KA; McAteer JB; Franks PW; Mason CC; Mather K; Horton E; Goldberg R; Dabelea D; Kahn SE; Arakaki RF; Shuldiner AR; Knowler WC;
PLoS One; 2012; 7(9):e44424. PubMed ID: 22984506
[TBL] [Abstract][Full Text] [Related]
12. Type 2 Diabetes and Adiposity Induce Different Lipid Profile Disorders: A Mendelian Randomization Analysis.
Wang N; Cheng J; Ning Z; Chen Y; Han B; Li Q; Chen C; Zhao L; Xia F; Lin D; Guo L; Lu Y
J Clin Endocrinol Metab; 2018 May; 103(5):2016-2025. PubMed ID: 29506267
[TBL] [Abstract][Full Text] [Related]
13. Advanced lipoprotein profile disturbances in type 1 diabetes mellitus: a focus on LDL particles.
Amor AJ; Castelblanco E; Hernández M; Gimenez M; Granado-Casas M; Blanco J; Soldevila B; Esmatjes E; Conget I; Alonso N; Ortega E; Mauricio D
Cardiovasc Diabetol; 2020 Aug; 19(1):126. PubMed ID: 32772924
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of low-density lipoprotein particle number distribution in patients with type 2 diabetes mellitus with low-density lipoprotein cholesterol <50 mg/dl and non-high-density lipoprotein cholesterol <80 mg/dl.
Malave H; Castro M; Burkle J; Voros S; Dayspring T; Honigberg R; Pourfarzib R
Am J Cardiol; 2012 Sep; 110(5):662-5. PubMed ID: 22621796
[TBL] [Abstract][Full Text] [Related]
15. Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the diabetes prevention program.
Ratner R; Goldberg R; Haffner S; Marcovina S; Orchard T; Fowler S; Temprosa M;
Diabetes Care; 2005 Apr; 28(4):888-94. PubMed ID: 15793191
[TBL] [Abstract][Full Text] [Related]
16. Interactions of Lipid Genetic Risk Scores With Estimates of Metabolic Health in a Danish Population.
Justesen JM; Allin KH; Sandholt CH; Borglykke A; Krarup NT; Grarup N; Linneberg A; Jørgensen T; Hansen T; Pedersen O
Circ Cardiovasc Genet; 2015 Jun; 8(3):465-72. PubMed ID: 25714099
[TBL] [Abstract][Full Text] [Related]
17. Common lipid-altering gene variants are associated with therapeutic intervention thresholds of lipid levels in older people.
Murray A; Cluett C; Bandinelli S; Corsi AM; Ferrucci L; Guralnik J; Singleton A; Frayling T; Melzer D
Eur Heart J; 2009 Jul; 30(14):1711-9. PubMed ID: 19435741
[TBL] [Abstract][Full Text] [Related]
18. Shared common variants in prostate cancer and blood lipids.
Andreassen OA; Zuber V; Thompson WK; Schork AJ; Bettella F; ; ; Djurovic S; Desikan RS; Mills IG; Dale AM
Int J Epidemiol; 2014 Aug; 43(4):1205-14. PubMed ID: 24786909
[TBL] [Abstract][Full Text] [Related]
19. Long-term effects on lipids and lipoproteins of pioglitazone versus gliclazide addition to metformin and pioglitazone versus metformin addition to sulphonylurea in the treatment of type 2 diabetes.
Betteridge DJ; Vergès B
Diabetologia; 2005 Dec; 48(12):2477-81. PubMed ID: 16283239
[TBL] [Abstract][Full Text] [Related]
20. Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study. The Pioglitazone 027 Study Group.
Einhorn D; Rendell M; Rosenzweig J; Egan JW; Mathisen AL; Schneider RL
Clin Ther; 2000 Dec; 22(12):1395-409. PubMed ID: 11192132
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
